<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22826" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Heroin (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huecker</surname>
            <given-names>Martin R.</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koutsothanasis</surname>
            <given-names>George A.</given-names>
          </name>
          <aff>Wyckoff Heights Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abbasy</surname>
            <given-names>Muhammad Shamil U.</given-names>
          </name>
          <aff>Ziauddin Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marraffa</surname>
            <given-names>Jeanna</given-names>
          </name>
          <aff>Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Martin Huecker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>George Koutsothanasis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Shamil Abbasy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeanna Marraffa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22826.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Heroin, also known as diacetylmorphine, is derived from the opium poppy plant.<xref ref-type="bibr" rid="article-22826.r1">[1]</xref>&#x000a0;Bayer Pharmaceuticals developed the diacetylmorphine molecule in 1898&#x000a0;as an antitussive.<xref ref-type="bibr" rid="article-22826.r1">[1]</xref>&#x000a0;Professionals initially touted morphine as a&#x000a0;substitute with less addiction potential. Heroin currently&#x000a0;has no FDA-approved indications for use. Heroin is a Schedule I drug under the Controlled Substances Act of 1970,&#x000a0;with no approved medical use in the United States.<xref ref-type="bibr" rid="article-22826.r2">[2]</xref>&#x000a0;The United Kingdom allows the use of heroin, known under the generic name of diamorphine, for diverse analgesic indications such as postoperative pain, chronic pain, palliative care, and even post-cesarean section.<xref ref-type="bibr" rid="article-22826.r3">[3]</xref></p>
        <p>Heroin's chief place&#x000a0;in American healthcare remains problematic. As an illicit opioid, people have misused heroin for decades.<xref ref-type="bibr" rid="article-22826.r4">[4]</xref>&#x000a0;In the 21st century, the use of heroin has caused a&#x000a0;surge in both dependence and overdose deaths.<xref ref-type="bibr" rid="article-22826.r5">[5]</xref>&#x000a0;Though people in other countries use heroin, in the United&#x000a0;States, it has no&#x000a0;recognized&#x000a0;therapeutic role in managing opioid addiction.&#x000a0;</p>
      </sec>
      <sec id="article-22826.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Heroin is synthetically derived from the morphine alkaloid in opium and is approximately twice as potent as morphine. Heroin acts agonistically on the central nervous system (CNS) opioid receptors&#x000a0;mu, kappa, and delta.<xref ref-type="bibr" rid="article-22826.r1">[1]</xref>&#x000a0;Mu receptor effects account for both the analgesic effects (Mu1) and the respiratory depression and euphoria (Mu2).<xref ref-type="bibr" rid="article-22826.r6">[6]</xref>&#x000a0;Activation of Mu2 receptors also causes miosis, reduced gastrointestinal (GI) motility, and physiologic dependence. Kappa receptor activation causes some&#x000a0;degree of&#x000a0;analgesia&#x000a0;as well.<xref ref-type="bibr" rid="article-22826.r6">[6]</xref>&#x000a0;Delta receptors are more involved in spinal analgesia phenomena.</p>
        <p>Heroin&#x000a0;metabolizes in the CNS to monoacetylmorphine, which is a more potent mu-receptor agonist than morphine.<xref ref-type="bibr" rid="article-22826.r6">[6]</xref>&#x000a0;Peripheral tissues metabolize heroin to 6-monoacetylmorphine and then morphine.<xref ref-type="bibr" rid="article-22826.r1">[1]</xref>&#x000a0;Many state toxicology labs use the 6-monoacetylmorphine to determine which overdose deaths were due to heroin.</p>
        <p>When taken orally, heroin undergoes first-pass metabolism to morphine via deacetylation. Therefore, unlike intravenous administration, oral ingestion does not cause a rapid onset of effects and is less desirable to users. 6-monoacetylmorphine and morphine activate opioid receptors.<xref ref-type="bibr" rid="article-22826.r7">[7]</xref></p>
      </sec>
      <sec id="article-22826.s3" sec-type="Administration">
        <title>Administration</title>
        <p>As mentioned above, practitioners in the United States do not administer heroin in any sanctioned healthcare setting. Illicitly, people misuse heroin via subcutaneous, intranasal, intramuscular, and intravenous methods. Heroin is highly lipophilic and, therefore, rapidly crosses the blood-brain barrier.<xref ref-type="bibr" rid="article-22826.r1">[1]</xref>&#x000a0;All routes of administration lead to the rapid absorption of heroin.&#x000a0;Peak serum levels in these routes are 5 to&#x000a0;10 minutes subcutaneously,&#x000a0;3 to&#x000a0;5 minutes intranasally and intramuscularly, and less than one minute intravenously.<xref ref-type="bibr" rid="article-22826.r8">[8]</xref></p>
        <p>Once absorbed into the serum, heroin reaches the brain in 15 to 20 seconds. While less than 5% of intravenous morphine reaches the brain, 68% of intravenous heroin makes contact with&#x000a0;receptors in the brain. This rapid effect gives the user a rush that typically leads to continued use,&#x000a0;with the desired outcome of&#x000a0;achieving that same first experience of euphoria.<xref ref-type="bibr" rid="article-22826.r9">[9]</xref></p>
      </sec>
      <sec id="article-22826.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The intended effects of heroin misuse are those classically associated with any opioid effects. These are analgesia, euphoria, and often alleviation of opioid withdrawal symptoms. All other effects of heroin could be considered adverse. Respiratory depression is likely the most concerning adverse effect, leading to death in an increasing number of misusers. Extreme physiologic dependence also represents a major concern in those who misuse heroin.</p>
        <p>Heroin reliably causes&#x000a0;decreased GI motility, which commonly leads to constipation.<xref ref-type="bibr" rid="article-22826.r10">[10]</xref>&#x000a0;This&#x000a0;decreased motility can be problematic enough for users who may require medical attention to relieve constipation. Miosis represents a minimal concern to healthcare providers or those abusing the drug, though this effect can have diagnostic value.</p>
        <p>Some practitioners have described severe, life-threatening pulmonary edema in patients who misuse or overdose on heroin.<xref ref-type="bibr" rid="article-22826.r11">[11]</xref>&#x000a0;This edema is noncardiogenic and likely relates to increased pulmonary vascular permeability. Practitioners have also attributed cases of compartment syndrome to heroin use.<xref ref-type="bibr" rid="article-22826.r12">[12]</xref></p>
      </sec>
      <sec id="article-22826.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Because the FDA recognizes no medical use for heroin, it has not specified any contraindications. In countries where people use the drug for medicinal&#x000a0;purposes, hypersensitivity and the potential for misuse or dependence could be perceived as contraindications.</p>
        <p>Canada lists heroin as a Schedule I drug in the Controlled Drugs and Substances Act.<xref ref-type="bibr" rid="article-22826.r13">[13]</xref> Various countries have enforced different&#x000a0;levels of criminal regulation related to heroin.&#x000a0;</p>
      </sec>
      <sec id="article-22826.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Again, with no approved use for heroin, no therapeutic index exists. However, pharmacodynamically, heroin could be considered to have a very&#x000a0;narrow therapeutic window. Due to potency and concentration variations, users are unaware of the actual amount of the&#x000a0;active drug in any given&#x000a0;sample.<xref ref-type="bibr" rid="article-22826.r14">[14]</xref>&#x000a0;Therefore, the same apparent dose that causes euphoria one day could very&#x000a0;well lead to an overdose the next. Drug levels are not typically useful, though toxicology assessments post-mortem may quantify several metabolites.<xref ref-type="bibr" rid="article-22826.r7">[7]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22826.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Professionals thoroughly describe heroin toxicity in the literature and popular media. With the high rate of prescription opioid addiction (see opioid use disorder) and the lower cost of heroin, many individuals have developed heroin dependence.<xref ref-type="bibr" rid="article-22826.r15">[15]</xref>&#x000a0;As discussed above, heroin (especially if administered intravenously) is likely to cause an overdose and death due to respiratory depression. From 2002 through 2013, heroin overdoses went from 0.7 deaths per 100,000 to 2.7.<xref ref-type="bibr" rid="article-22826.r16">[16]</xref>&#x000a0;In 2013, roughly 517,000 people reported heroin use in the past year, 1.5 times the amount in 2007.<xref ref-type="bibr" rid="article-22826.r17">[17]</xref>&#x000a0;State and federal legislation are implementing&#x000a0;diverse methods to curb this epidemic of heroin overdose deaths. The many infectious and economic effects of heroin dependence add to the risk of death.</p>
        <p>The antidote for heroin overdose or poisoning is naloxone. Naloxone binds with high affinity to the Mu receptors in the CNS.<xref ref-type="bibr" rid="article-22826.r18">[18]</xref>&#x000a0;Administration of naloxone is an inverse agonist and, if given in a high enough dose, it induces withdrawal in an opioid-dependent patient.<xref ref-type="bibr" rid="article-22826.r18">[18]</xref>&#x000a0;Naloxone is also believed to block the binding of endogenous opioids. Practitioners can administer naloxone intravenously, intramuscularly, and increasingly intranasally. Many first responders now carry intranasal naloxone kits to reverse heroin or opioid overdose in field settings.&#x000a0;</p>
        <p>Naltrexone, a long-acting opioid antagonist, is available both orally and as a long-acting intramuscular injection. However, the risk of precipitating a prolonged withdrawal syndrome prohibits the use as an antidote for initial reversal.<xref ref-type="bibr" rid="article-22826.r19">[19]</xref>&#x000a0;Clinicians are using these long-acting opioid antagonists in medication-assisted treatment for patients with opioid use disorder.&#x000a0;</p>
      </sec>
      <sec id="article-22826.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Medication-assisted treatment represents an effective option for the treatment of heroin dependence and opioid use disorder in general. Buprenorphine and methadone are the chief agents used, with buprenorphine being more safe and effective. Buprenorphine also has a higher affinity for the mu-opioid receptors than heroin.<xref ref-type="bibr" rid="article-22826.r20">[20]</xref>&#x000a0;All interprofessional team members need to be alert and communicate to the rest of the team if there are any indications that a patient is engaged in misusing heroin so that appropriate interventions can take place.</p>
      </sec>
      <sec id="article-22826.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22826&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22826">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22826/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22826">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22826.s10">
        <title>References</title>
        <ref id="article-22826.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sneader</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The discovery of heroin.</article-title>
            <source>Lancet</source>
            <year>1998</year>
            <month>Nov</month>
            <day>21</day>
            <volume>352</volume>
            <issue>9141</issue>
            <fpage>1697</fpage>
            <page-range>1697-9</page-range>
            <pub-id pub-id-type="pmid">9853457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hunsaker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cornelius</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and consequences of heroin use among older adults in the United States: a review of the literature, treatment implications, and recommendations for further research.</article-title>
            <source>Addict Behav</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-85</page-range>
            <pub-id pub-id-type="pmid">21237575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metrebian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carnwath</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Carnwath</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stimson</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Sell</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pathways into receiving a prescription for diamorphine (heroin) for the treatment of opiate dependence in the United kingdom.</article-title>
            <source>Eur Addict Res</source>
            <year>2007</year>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>144</fpage>
            <page-range>144-7</page-range>
            <pub-id pub-id-type="pmid">17570910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cicero</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Surratt</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Kurtz</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>The changing face of heroin use in the United States: a retrospective analysis of the past 50 years.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2014</year>
            <month>Jul</month>
            <day>01</day>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>821</fpage>
            <page-range>821-6</page-range>
            <pub-id pub-id-type="pmid">24871348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Pickard</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>The societal cost of heroin use disorder in the United States.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e0177323</fpage>
            <pub-id pub-id-type="pmid">28557994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Heroin addiction: neurobiology, pharmacology, and policy.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>1991</year>
            <season>Apr-Jun</season>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-33</page-range>
            <pub-id pub-id-type="pmid">1662715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madea</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Confirmation of recent heroin abuse: Accepting the challenge.</article-title>
            <source>Drug Test Anal</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-71</page-range>
            <pub-id pub-id-type="pmid">28681463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinis-Oliveira</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Metabolism and metabolomics of opiates: A long way of forensic implications to unravel.</article-title>
            <source>J Forensic Leg Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>61</volume>
            <fpage>128</fpage>
            <page-range>128-140</page-range>
            <pub-id pub-id-type="pmid">30621882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gott&#x000e5;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnestad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Halvorsen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Bachs</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>H&#x000f8;iseth</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of heroin and its metabolites in vitreous humor and blood in a living pig model.</article-title>
            <source>Forensic Toxicol</source>
            <year>2016</year>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-285</page-range>
            <pub-id pub-id-type="pmid">27660664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasternak</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Mu Opioid Pharmacology: 40 Years to the Promised Land.</article-title>
            <source>Adv Pharmacol</source>
            <year>2018</year>
            <volume>82</volume>
            <fpage>261</fpage>
            <page-range>261-291</page-range>
            <pub-id pub-id-type="pmid">29413524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raja</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Flores</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wakeman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Case 37-2017. A 36-Year-Old Man with Unintentional Opioid Overdose.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>30</day>
            <volume>377</volume>
            <issue>22</issue>
            <fpage>2181</fpage>
            <page-range>2181-2188</page-range>
            <pub-id pub-id-type="pmid">29171813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harbrecht</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bozeman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Heroin-Related Compartment Syndrome: An Increasing Problem for Acute Care Surgeons.</article-title>
            <source>Am Surg</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>83</volume>
            <issue>9</issue>
            <fpage>962</fpage>
            <page-range>962-965</page-range>
            <pub-id pub-id-type="pmid">28958275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prangnell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fairgrieve</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nosova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>DeBeck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Milloy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>High Prevalence of Self-Reported Exposure to Adulterated Drugs Among People Who Experienced an Opioid Overdose in Canada: A Cohort Study.</article-title>
            <source>Subst Use Misuse</source>
            <year>2019</year>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>980</fpage>
            <page-range>980-985</page-range>
            <pub-id pub-id-type="pmid">30663484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olives</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>It's not just heroin anymore.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>608</fpage>
            <pub-id pub-id-type="pmid">28440696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faryar</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Persaud</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Furmanek</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Guinn</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Mattingly</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Wiemken</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Huecker</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Kentucky's Comprehensive Opioid Legislation on Patients Presenting with Prescription Opioid or Heroin Abuse to One Urban Emergency Department.</article-title>
            <source>J Emerg Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>805</fpage>
            <page-range>805-814</page-range>
            <pub-id pub-id-type="pmid">29102093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedegaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug-poisoning deaths involving heroin: United States, 2000-2013.</article-title>
            <source>NCHS Data Brief</source>
            <year>2015</year>
            <month>Mar</month>
            <issue>190</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">25932890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gladden</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bohm</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2015</year>
            <month>Jul</month>
            <day>10</day>
            <volume>64</volume>
            <issue>26</issue>
            <fpage>719</fpage>
            <page-range>719-25</page-range>
            <pub-id pub-id-type="pmid">26158353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skolnick</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>On the front lines of the opioid epidemic: Rescue by naloxone.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>15</day>
            <volume>835</volume>
            <fpage>147</fpage>
            <page-range>147-153</page-range>
            <pub-id pub-id-type="pmid">30092179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carreiro</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Brush</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Potential uses of naltrexone in emergency department patients with opioid use disorder.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>753</fpage>
            <page-range>753-759</page-range>
            <pub-id pub-id-type="pmid">30831039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22826.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Onofrio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chawarski</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Pantalon</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Hawk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fiellin</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.</article-title>
            <source>J Gen Intern Med</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>660</fpage>
            <page-range>660-666</page-range>
            <pub-id pub-id-type="pmid">28194688</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
